Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes
NCT04769167
Autoimmune Diseases, Cardiovascular Abnormalities
St Louis, Missouri, United States
View Trial DetailsNCT Number: NCT00722241
The purpose of this study is to evaluate the safety and effectiveness of the next-generation DexCom SEVEN Continuous Glucose Monitoring System (SEVEN.2 System) when worn for up to 7-days by subjects >18 years-old with diabetes mellitus requiring insulin therapy.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
John Muir Physician Network Clinical Research Center, Concord, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Days 1, 4, and 7 of Sensor wear
DexCom, Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04769167
Autoimmune Diseases, Cardiovascular Abnormalities
St Louis, Missouri, United States
View Trial DetailsNCT01407640
Allergy, Autoimmune Diseases
Paris, France
View Trial DetailsNCT03908125
Autoimmune Diseases, Diabetes Mellitus
Newport Beach, California, United States
View Trial DetailsNCT04869761
Autoimmune Diseases, Chronic Disease
Jacksonville, Florida, United States
View Trial Details